New coumarins from a hot water extract of Daphne mezereum bark

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-03-26 DOI:10.1016/j.phytol.2025.102954

Hussain Shakeel Butt , Lucía Bada , Karl Egil Malterud , Kari Tvete Inngjerdingen , Helle Wangensteen

{"title":"New coumarins from a hot water extract of Daphne mezereum bark","authors":"Hussain Shakeel Butt , Lucía Bada , Karl Egil Malterud , Kari Tvete Inngjerdingen , Helle Wangensteen","doi":"10.1016/j.phytol.2025.102954","DOIUrl":null,"url":null,"abstract":"<div><div>This study aimed to investigate the low-molecular weight compounds in a hot water extract of the bark of <em>Daphne mezereum</em> L. (Thymelaceae), a medicinal plant with a longstanding medicinal use in Scandinavia. Among the fourteen isolated compounds, two coumarin glycosides are reported for the first time, and four known compounds were reported in <em>D. mezereum</em> for the first time. Their structures were elucidated by NMR, HRESIMS and methanolysis. The new compounds were identified as 3-(2-(β-<span>d</span>-glucopyranosyloxy)-4-[(7-hydroxy-6-methoxy-2-oxo-2H-chromen-3-yl)oxy]phenyl)propanoic acid (<strong>9</strong>), and 7-hydroxycoumarin-5,8-di-β-<span>d</span>-glucopyranoside (<strong>11</strong>). Cytotoxic effects were assessed by the MTT assay, while the anti-inflammatory effects were assessed by measuring the inhibition of NO-release by dendritic cells. The results revealed negligible cytotoxic effect and NO-inhibitory activity of compounds <strong>9</strong> and <strong>11</strong>.</div></div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"67 ","pages":"Article 102954"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874390025010432","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to investigate the low-molecular weight compounds in a hot water extract of the bark of Daphne mezereum L. (Thymelaceae), a medicinal plant with a longstanding medicinal use in Scandinavia. Among the fourteen isolated compounds, two coumarin glycosides are reported for the first time, and four known compounds were reported in D. mezereum for the first time. Their structures were elucidated by NMR, HRESIMS and methanolysis. The new compounds were identified as 3-(2-(β-d-glucopyranosyloxy)-4-[(7-hydroxy-6-methoxy-2-oxo-2H-chromen-3-yl)oxy]phenyl)propanoic acid (9), and 7-hydroxycoumarin-5,8-di-β-d-glucopyranoside (11). Cytotoxic effects were assessed by the MTT assay, while the anti-inflammatory effects were assessed by measuring the inhibition of NO-release by dendritic cells. The results revealed negligible cytotoxic effect and NO-inhibitory activity of compounds 9 and 11.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.